Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954745 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01954745: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01954745 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01954745, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research study is evaluating a drug called cabozantinib as a possible treatment cancer of the bile duct. Cabozantinib is a drug that targets specific pathways inside the cells of the body. By blocking the c-MET and VEGFR2 pathways from sending signals, cabozantinib may prevent cells from multiplying. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to stop the growth of bile duct cancer. In this research study, the investigators are looking to see how well cabozantinib works in slowing the growth of bile duct cancer. The investigators are also assessing the safety and tolerability of cabozantinib in participants with this type of cancer.
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954745
The ClinicalTrials.gov registry entry for NCT01954745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT01954745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01954745 about?
NCT01954745 is a clinical study titled "Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma". This research study is evaluating a drug called cabozantinib as a possible treatment cancer of the bile duct. Cabozantinib is a drug that targets specific pathways inside the cells of the body. By blocking the c-MET and VEGFR2 pathways from sending signals, cabozantinib may prevent cells from multip...
What is the current status of trial NCT01954745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2013-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01954745?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT01954745?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.